58 results about "Newcastle disease" patented technology

The present disclosure relates to the expression of recombinant viral antigens using transgenic fungi. Compositions, production and administration of vaccines comprising those viral antigens are also disclosed. In some embodiments, these viral antigens can be used to formulate vaccines against Newcastle disease. These vaccines may be administered, for example, by intramuscular injection.

The invention provides a traditional Chinese medicine feed additive for improving animal immunity and a preparation method thereof, and relates to the technical field of traditional Chinese medicine feed additives. The traditional Chinese medicine feed additive is prepared from twelve traditional Chinese medicines including astragalus membranaceus, immature bitter orange, fructus forsythiae, black beans, semen cuscutae, radix paeoniae alba, rosemary, thyme, litsea cubeba, mangosteen peel, cinnamon and origanum vulgare. The traditional Chinese medicine feed additive disclosed by the invention can be used for improving the immune organ index of an immunosuppressed mouse induced by cyclophosphamide, regulating the level of immune protein and inflammation-related factors and enhancing the phagocytic ability of macrophages of the mouse; the antibody titer of the Newcastle disease virus can be improved, the immune organ index of the chicken can be improved, and the secretion of IL-4, TNF-alpha and IFN-gamma in the chicken body can be promoted; mouse and broiler chicken tests show that the traditional Chinese medicine feed additive disclosed by the invention can improve the immune response capability of animals and enhance the immunity of the animals, and has a good application prospect in animal breeding.

The invention belongs to the technical field of biology, and discloses a TaqMan primer probe combination for detecting virulent and attenuated Newcastle disease, which comprises a virulent primer RT, a virulent probe RT-probe, a universal primer SRT and a universal probe SRT-probe, the virulent primer RT comprises an upstream primer RT-F and a downstream primer RT-R, and the universal primer SRT comprises an upstream primer SRT-F and a downstream primer SRT-R; a TaqMan probe fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection method for virulent and attenuated NDV (Newcastle Disease Virus) established by using the TaqMan primer probe combination has no cross reaction on amplification of common avian viruses AIV, FADV, IBV and IBDV and has good specificity; the lowest detection concentration of virulent and attenuated Newcastle disease virus is 101 copies / uL, which is 100 times higher than that of a conventional RT-PCR method, and the kit has good sensitivity; and compared with the conventional RT-PCR method, the detection rate is 100% and is superior to that of the conventional RT-PCR method, and the detection result is consistent with the sequencing result.

The application discloses a chicken Newcastle disease, avian influenza and chicken infectious rhinitis triple inactivated vaccine and preparation and application thereof, and relates to the technical field of bioengineering. The application discloses a preparation method and application of a chicken Newcastle disease, avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine. The preparation method comprises the following steps: constructing and expressing a serum B paracolon avian bacillus subunit protein expression strain; and preparing the chicken Newcastle disease, H9 subtype avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine at a certain ratio. The triple inactivated vaccine has good safety, can be used for the prevention of chicken Newcastle disease, H9 subtype avian influenza and A, B and C three serotypes paracolon avian bacillus diseases in a laying hen group, and does not cause the decrease of the laying rate after immunization. Meanwhile, the paracolon avian bacillus subunit protein can improve the antibody level of the Newcastle disease and the H9 avian influenza, and the protection of the vaccine on the A, B and C three serotypes paracolon avian bacillus can reach 100%.

The invention discloses a recombinant serum 4 type fowl adenovirus FAdV4-IBV-QXS1-rf2 carrying an infectious bronchitis S1 gene, wherein a gene locus of the serum 4 type fowl adenovirus Fiber-2 is replaced by an S1 protein gene of an infectious bronchitis virus QX subtype. According to the FAdV4-IBV-QXS1-rf2 recombinant virus, the CRISPR / cas9 technology is used for gene editing of the serum type 4 fowl adenovirus, the pathogenicity of the virus is reduced, meanwhile, high immunogenicity is reserved, and the FAdV4-IBV-QXS1-rf2 recombinant virus which is high in purity and can be inherited stably is obtained. The recombinant virus can activate mucous membrane and humoral immunity of chicken, achieves a dual immune protection effect on FAdV-4 and IBV-QX infection, overcomes the defect of single targeting of traditional vaccines, and provides a general technical path for research and development of multi-combined vaccines of avian influenza, Newcastle disease and other poultry viruses.

Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.

The present invention provides recombinant Newcastle disease virus (NDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 delta variant spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 delta variant spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS-CoV-2 delta variant as well as the prevention of COVID-19.

The invention relates to the technical field of poultry disease detection, in particular to a hemagglutination test detection method for avian influenza and Newcastle disease. The invention does not perform hemagglutination tests for avian influenza and Newcastle disease, but sets 9log2 and 10log2 as reference hemagglutination titers for hemagglutination tests for avian influenza and Newcastle disease, respectively, prepares corresponding 4HAU antigens according to "Avian influenza and Newcastle disease 4HAU antigen preparation table", directly performs regression test, observes the number of erythrocyte agglutination holes, and calculates accurate avian influenza hemagglutination titer or Newcastle disease hemagglutination titer according to the observed result of the regression test according to the avian influenza hemagglutination titer formula or the Newcastle disease hemagglutination titer formula, without repeated test verification, thereby greatly improving the diagnostic efficiency of the avian influenza and Newcastle disease hemagglutination tests.

The invention belongs to the technical field of quadruple vaccine research and development, and particularly relates to a preparation method of a chicken new flow glandular synovial quadruple vaccine, which comprises the following steps: step one, strain selection: selecting a Newcastle disease LaSota strain, an avian influenza H9 subtype NJ02 strain, a chicken glandular FADV-4 strain and a chicken synovial sac HN01 strain; the selected Newcastle disease strain, the selected avian influenza strain, the selected chicken gland strain and the selected chicken synovial sac strain are inoculated in different culture solutions for culture amplification, the culture environment is controlled to be about 37 DEG C (the temperature before and after the culture is not larger than 0.5 DEG C), and the strain culture time is controlled to be 2-4 days. By selecting the Newcastle disease LaSota strain, the avian influenza H9 subtype NJ02 strain, the chicken gland FADV-4 strain and the chicken synovial sac HN01 strain, the subsequent quadruple vaccine prevention effect can be guaranteed, sufficient quadruple vaccine raw materials can be provided through strain culture, and the production efficiency is guaranteed.

The invention relates to the field of virus detection, in particular to a kit, primer and probe combination for simultaneously detecting avian influenza virus, Newcastle disease virus and infectious bronchitis virus. The kit disclosed by the invention comprises a nucleic acid amplification reagent, wherein the nucleic acid amplification reagent contains primers as shown in SEQ ID NO: 1 to SEQ ID NO: 6 and probes as shown in SEQ ID NO: 7 to SEQ ID NO: 9. The invention designs three pairs of primers and probes aiming at three pathogens of avian influenza virus, Newcastle disease virus and infectious bronchitis virus, and the primers and probes have good sensitivity and specificity and do not have non-specific reaction.

Described herein are recombinant Newcastle disease viruses ("NDVs") comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 delta variant spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 delta variant spike protein ectodomain and NOV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS- CoV-2 delta variant as well as the prevention of COVID-19.

Described herein are recombinant Newcastle disease viruses ("NDVs") comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NOV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of CO VID-19.

The invention discloses a primer probe composition for detecting AIV, NDV virulent strains and IBV, a kit and application, and belongs to the technical field of fluorescence detection. The sequence of the primer probe combination is shown as SEQ ID NO.1-SEQ ID NO.9, the primer probe combination comprises a primer pair and a probe for detecting the avian influenza virus, the Newcastle disease virus virulent strain and the avian infectious bronchitis virus, and the primer probe combination can be used for detecting and distinguishing all subtypes of the avian influenza virus and the Newcastle disease virus virulent strain and different genotypes of the avian infectious bronchitis viruses. The kit is high in specificity and sensitivity, does not have cross reaction with other common viruses, and is high in detection sensitivity, and the minimum detectable quantity of the three viruses is 0.8 copy, so that the specific, sensitive and rapid detection of AIV, NDV and IBV can be realized, and the defects of the conventional detection technology are overcome. The method has important practical significance on timely blocking epidemic situation propagation, reducing breeding loss, guaranteeing public health safety and the like.

The invention belongs to the field of Newcastle disease treatment formulas, and provides a Newcastle disease treatment traditional Chinese medicine scheme, which comprises the following raw materials: gypsum, rhizoma anemarrhenae, honey-fried licorice root, and purified water. Through the pure traditional Chinese medicine formula, antibiotics and chemical drugs are not needed, drug residues are avoided after use, drug resistance to poultry is avoided, side effects are avoided, isolation treatment does not need to be conducted on diseased poultry during use, medicine can be directly fed, and the traditional Chinese medicine composition has the advantages of being easy to operate, low in medication cost, short in treatment time and remarkable in treatment effect.

This invention discloses a primer composition, kit, and application for avian pathogens. The primer composition comprises a crRNA with the sequence shown in SEQ ID NO: 1, an RT-RAA upstream primer with the sequence shown in SEQ ID NO: 2, and an RT-RAA downstream primer with the nucleotide sequence shown in SEQ ID NO: 3. It may also include a fluorescent probe with the sequence TTTTT. This primer composition can be used for the detection of avian infectious bronchitis virus, exhibiting high specificity and no cross-reactivity with common avian viruses such as avian influenza virus, Newcastle disease virus, and infectious laryngotracheitis virus. Furthermore, the primer composition has high sensitivity, with a detection limit as low as 4.25 × 10⁻⁶. 2 The primer composition exhibits high copy number / μL, good reproducibility, and stable results. It is suitable for single-tube isothermal nucleic acid amplification detection, offering mild reaction conditions and significantly reduced detection time, demonstrating excellent industrial application value.

The present invention relates to a pharmaceutical composition for cancer treatment, comprising recombinant Newcastle disease virus vectors. The recombinant Newcastle disease virus vectors OncoK148 and OncoK14-318, which are the products of the present invention, are oncolytic viruses which are types of cancer immunotherapy agents, and may be used as cancer therapeutic agents in various animal species such as dogs, cats, humans, etc.

The invention relates to the field of biomedical treatment, in particular to application of RhoA protein in preparation of a product for enhancing the treatment effect of tumor oncolytic virus. The amino acid sequence of the RhoA protein is shown as SEQ ID NO.1. Aiming at the problems that oncolytic viruses including the Newcastle disease virus are narrow in treatment spectrum and insufficient in tumor killing efficacy, the human RHOA gene is introduced through a gene recombination technology and serves as an enhancer, and the anti-tumor effect of the Newcastle disease virus is improved. The recombinant oncolytic virus disclosed by the invention has a broad-spectrum and excellent anti-tumor effect. A further research finds that the recombinant oncolytic virus can induce tumor cell acute mitochondrial active oxygen excess generation to trigger lipid peroxidation to cause autophagic cell death, which is a main mechanism for mediating efficient oncolytic of the recombinant oncolytic virus. Research results show that the recombinant oncolytic virus is a breakthrough candidate drug for overcoming the clinical treatment problem of tumor heterogeneity, and has a good clinical application prospect.

The present invention provides recombinant Newcastle disease virus (NDV) viral vectors comprising heterologous polynucleotides encoding avian influenza antigens. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines and are capable of providing protection against avian influenza and other pathogens when administered to avians.

The invention discloses a recombinant turkey herpesvirus strain as well as a construction method and application thereof, and belongs to the technical field of medicine or veterinary medicine. The recombinant turkey herpesvirus is a recombinant turkey herpesvirus strain co-expressing a Newcastle disease virus F gene and infectious laryngotracheitis virus gB, gD and gI genes or a recombinant turkey herpesvirus strain co-expressing a Newcastle disease virus F gene, a chicken infectious bursal disease virus VP2 gene and infectious laryngotracheitis virus gB, gD and gI genes. The recombinant turkey herpesvirus strain obtained by the invention has good in-vitro replication ability and genetic stability. Safety and immunogenicity experiments prove that the two recombinant turkey herpesvirus strains are safe to SPF chickens and have good immune protection effects on NDV virulent strains, ILTV virulent strains and IBDV virulent strains. The invention provides an effective technical means for simultaneously preventing the Newcastle disease and the chicken infectious laryngotracheitis or simultaneously preventing the Newcastle disease, the chicken infectious bursal disease and the chicken infectious laryngotracheitis.

The invention belongs to the technical field of biology, and discloses construction and application of a recombinant herpesvirus of turkey for co-expressing an HA gene and an F gene, and the recombinant herpesvirus of turkey for co-expressing the HA gene and the F gene is characterized in that a target gene 1 and a target gene 2 are respectively inserted between an HVT053 site and an HVT054 site and between an HVT065 site and an HVT066 site in a UL region of the herpesvirus of turkey; or respectively inserting the target gene 1 and the target gene 2 between the HVT053 site and the HVT054 site and between the HVT087 site and the HVT088 site in the UL region of the turkey herpesvirus; and respectively obtaining a recombinant virus 1 and a recombinant virus 2. The two recombinant turkey herpesviruses can grow, replicate and stably inherit in vitro, and a good immune protection effect is provided for H9N2 subtype avian influenza and Newcastle disease. Meanwhile, the invention also provides application and a vaccine of the recombinant herpesvirus of turkeys.

The invention provides a multifunctional mimic oncolytic virus nano-drug as well as a preparation method and application thereof. The multifunctional mimic oncolytic virus nano-drug comprises vesicles and a substance with a pyroptosis induction function, the vesicle is a shell of the multifunctional oncolytic virus imitating nano-drug; a substance with a pyroptosis induction function is loaded in the shell; the vesicles are formed by hybridizing an engineered cell membrane simulating a Newcastle disease virus envelope and a macrophage cell membrane; the multifunctional mimic oncolytic virus nano-drug realizes tumor killing, immune activation and tumor targeting through the characteristics of pyroptosis and oncolytic virus. The mimic oncolytic virus cell membrane and the macrophage cell membrane are hybridized to form the vesicles, and the vesicles are used as a shell of the drug to load the substance with the pyroptosis induction function in the vesicles, so that the in-vivo circulation time of the nanoparticles is prolonged, immune clearance caused by virus protein modification is avoided, and the drug delivery efficiency is improved. Therefore, the enrichment degree of the nanoparticles in tumors is further improved.

A bacteria-based compound for the prevention and treatment of a number of strains of avian influenza via oral intake by way of feed or drinking water or both. The agent is an inventive treatment compound comprising a bacterial-based culture which is directed to the prevention and treatment of avian influenza primarily for use in commercial birds such as poultry. The inventive treatment compound disclosed herein is produced from a lipopolysaccharide of a Gram-negative bacterial strain of the Brevundimonas group. The compound may be delivered to poultry by way of liquid or dry feed according to an effective prescribed regimen. A similar treatment approach may be taken as well after the bird is infected. Use of the composition is effective in the prevention and treatment of a variety of avian influenza, including high pathogenicity avian influenza, low pathogenicity avian influenza, Newcastle disease virus, infectious bronchitis disease virus, and infectious laryngotracheitis virus.

Described herein is a recombinant Newcastle Disease Virus ("NDV") comprising a packaged genome, the packaged genome comprising a transgene comprising a nucleotide sequence encoding a protein comprising the spike protein of SARS-CoV-2 or a portion thereof. Also described herein is a recombinant NDV comprising a packaged genome, the packaged genome comprising a transgene encoding a chimeric F protein, the chimeric F protein comprising the extracellular domain of the spike protein of SARS-CoV-2 and the transmembrane and cytoplasmic domains of the NDV F protein. Also described herein is an immunogenic composition comprising the recombinant NDV. The recombinant NDV and immunogenic composition are useful for immunizing against SARS-CoV-2 and preventing COVID-19.

Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.

Provided herein are polynucleotides encoding Lassa virus glycoprotein or Lassa virus nucleoprotein, or a chimeric protein comprising the ectodomain of Lassa virus glycoprotein and the transmembrane and cytoplasmic domains of NDV F protein. Also, provided herein are recombinant Newcastle disease virus (NDV) comprising such a polynucleotide, and immunogenic compositions comprising such recombinant NDV. Further, provided herein are methods for immunizing against Lassa virus comprising administering the recombinant NDV or an immunogenic composition thereof.

Described herein is a recombinant Newcastle disease virus ("NDV") comprising a packaging genome wherein the packaging genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or a portion thereof. Also described herein are recombinant NDVs comprising a packaging genome wherein the packaging genome comprises a transgene encoding a chimeric F protein wherein the chimeric F protein comprises an SARS-CoV-2 spike protein extracellular domain and an NDV F protein transmembrane domain and a cytoplasmic domain. In addition, immunogenic compositions comprising the recombinant NDV are described herein. The recombinant NDV and immunogenic compositions can be used to immunize against SARS-CoV-2 as well as to prevent COVID-19.

The invention discloses a primer probe composition for detecting H9 subtype AIV, NDV and IBV, a kit and application, and belongs to the technical field of fluorescence detection. The sequence of the primer probe combination is shown as SEQ ID NO.1-SEQ ID NO.9, the primer probe combination comprises a primer pair and a probe for detecting the H9 subtype avian influenza virus, the Newcastle disease virus and the infectious bronchitis virus, can detect and distinguish epidemic H9 viruses of different branches, NDV of different genotypes and IBV of different genotypes, does not have cross reaction with other common viruses, and can be used for detecting and distinguishing the H9 viruses of different branches, the NDV of different genotypes and the IBV of different genotypes. The detection sensitivity is high, and the minimum detectable quantity of the three viruses is 0.8 copy, so that the specific, sensitive and rapid detection of H9, NDV and IBV can be realized, and the defects of the existing traditional detection technology are overcome. The method has important practical significance on timely blocking epidemic situation propagation, reducing breeding loss, guaranteeing public health safety and the like.

The present invention relates to recombinant oncolytic viruses comprising a vesicular stomatitis virus (VSV), wherein the glycoprotein (G protein) of VSV is deleted; and which comprises a modified fusion protein (F protein) of Newcastle disease virus (NDV); and the hemagglutinin neuraminidase (HN) protein of NDV. The present invention further relates to nucleic acids encoding for the recombinant oncolytic virus and vectors comprising the nucleic acids. The present invention further relates to pharmaceutical compositions comprising the rVSV of the invention, the nucleic acid or the vector, further to uses as gene delivery tool and / or for tumor detection. The present invention further relates to the recombinant oncolytic vesicular stomatitis virus (VSV) for use in medicine, in particular for the diagnosis, prevention and / or treatment of cancer.

The invention discloses a preparation method of a small peptide zinc feed additive for improving immunity of broiler chickens, and relates to the technical field of feed additives.The method comprises the steps that soybean protein isolate and casein are mixed and then subjected to primary enzymolysis through pepsin, and then synergistic enzymolysis is conducted through neutral protease and flavourzyme; and carrying out ultrafiltration to obtain a small peptide component with the molecular weight of less than 1000 Daltons, chelating the small peptide component with zinc sulfate heptahydrate according to a molar ratio of 1: 2, carrying out spray drying to obtain a finished product, finally carrying out quality detection on the finished product, and carrying out sealing and dark preservation to obtain a qualified product. The invention aims to solve the problems of uncontrollable immune active components, insufficient efficacy verification and non-environment-friendly process in the existing feed additive, and can directionally enrich Arg-Gly-Asp, Lys-Pro and other immune active peptide fragments to form a high-stability small peptide zinc chelate, significantly improve the antibody titer, serum IgG level and intestinal barrier function of the broiler Newcastle disease, and improve the immunity of the broiler Newcastle disease. Meanwhile, the process is clean, low in cost and suitable for industrial production.